ReviewJournal of neuro-oncology
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.
Review in Journal of neuro-oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer.Frontiers in oncology · 2022Review
- The development of dendritic cell vaccine-based immunotherapies for glioblastoma.Seminars in immunopathology · 2017Review
- Emerging immunotherapies for glioblastoma.Expert opinion on emerging drugs · 2016Review
- Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.Future oncology (London, England) · 2013Review
- Glioma stem cell-targeted dendritic cells as a tumor vaccine against malignant glioma.Yonsei medical journal · 2013Article
- EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice.Cancer investigation · 2011Article
- Review
- DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.Neuro-oncology · 2009Article
- Therapeutic vaccines for malignant brain tumors.Biologics : targets & therapy · 2008Article
- Immunotherapy of malignant brain tumors.Immunological reviews · 2008Review
- Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.Journal of neuro-oncology · 2007Article
- Improving lesion detection and visualization: implications for neurosurgical planning and follow-up.Neuroradiology · 2007Review
- Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.Journal of neuro-oncology · 2007Article
- Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.Journal of immune based therapies and vaccines · 2007Article
- Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.Journal of translational medicine · 2006Article
- Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.Journal of Zhejiang University. Science · 2004Article
- Malignant gliomas.Current neurology and neuroscience reports · 2004Review
- Brain tumor immunotherapy: an immunologist's perspective.Journal of neuro-oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in therapeutic regimens, the prognosis remains poor for patients with malignant gliomas. Specificity has been an elusive goal for current modalities, but immunotherapy has emerged as a potential means of designing more tumor-specific treatments. Dendritic cells (DC) are the specialized antigen presenting cells of the immune system and have served now as a platform for therapeutic immunizations against such cancers as lymphoma, multiple myeloma, melanoma, prostate cancer, renal cell carcinoma, non-small cell lung carcinoma, colon cancer, and even malignant gliomas. DC-based immunizations offer a number of advantages over traditional immunotherapeutic approaches to brain tumors, approaches that have proved promising despite concerns over central nervous system immune privilege and glioma-mediated immunosuppression. The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration.
Indexed as
Identifiers
12952297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.